For the last seven years we have been interested in the specific treatment of lobar pneumonia. During this time several specific agents have been tried on monkeys with experimental pneumonia and on patients with lobar pneumonia in the wards of Bellevue Hospital. As a result of this rather extensive experience, we have arrived at certain conclusions which it seems worth while to publish.
In this paper we will attempt to elucidate the rationale of specific therapy in pneumonia and will state our present position on the whole subject. The experimental and clinical data reported have been published, in part, in previous scientific articles, but they are reprinted here for the purpose of exemplifying certain principles relative to the bacteriology and immunology of pneumococcus pneumonia.
TOXEMIA AND SEPTICEMIA
The great majority of acute infections pass through one or both of two stages: First, local infection, an inflammatory process in which the
BALDWIN HS, CECIL RL. THE RATIONALE OF SPECIFIC THERAPY IN PNEUMOCOCCUS PNEUMONIA. JAMA. 1926;87(21):1709–1715. doi:10.1001/jama.1926.02680210015005
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: